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Abstract 
Review on FIP1L1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Keywords 
FIP1L1; factor interacting with PAPOLA and 
CPSF1; cleavage and polyadenylation specificity 
factor complex; RNA-binding. 
Identity 
Other names: FIP1, Rhe, hFip1 
HGNC (Hugo): FIP1L1 
Location: 4q12 
Note 
Recommended name: Pre-mRNA 3'-end-processing 
factor FIP1. 
DNA/RNA 
Description 
Belongs to the FIP1 family; predicted to be under the 
control of a ubiquitous promoter (Gotlib et al., 
2004). 
Protein 
Description 
Contains a region (a 42-amino acid Fip1 motif) of 
homology to Fip1 (factor interacting with PAP), a 
yeast protein with synthetic lethal function that is 
involved in polyadenylation and transcriptional 
processes; N-terminus contains a PAP-binding site 
and its C-terminus has an arginine-rich RNA-
binding motif (Preker et al., 1995; Kaufmann et al., 
2004). 
Size: 4 isoforms as a result of splicing processes; the 
larger transcript has 594 amino acids (molecular 
weight 66526 Da). In the second isoform (559 amino 
acids; 63048 Da), exon 9 is deleted. The third 
isoform is the shortest (378 amino acids; molecular 
weight 40835 Da) due to the deletion of some exons 
(exon 2 and 14-18) during splicing processes. In the 
last isoform, exons 2, 9 and 11 are deleted. 
Expression 
FIP1L1 expression is present in different immunitary 
cells, embrionic and fetal cells, reproductive tissues, 
in blood and bone marrow and others. 
Localisation 
Subcellular location: Nucleus. 
Function 
FIP1L1 is an important part of the eukaryotic 
polyadenylation apparatus that plays a key role in 
polyadenylation of mRNA precursors (pre-mRNAs) 
by poly(A) polymerase (PAP). FIP1L1 is an integral 
component of the cleavage and polyadenylation 
specificity factor (CPSF) complex that is composed 
of CPSF1, CPSF2, CPSF3, CPSF4 and FIP1L. This 
multisubunit complex polyadenylates the 3' end of 
mRNA precursors by binding to the canonical 
AAUAAA signal and to U-rich sequences of mRNA 
precursors. The FIP1L1 protein is an important 
bridging factor in polyadenylation processes by 
providing links between RNA, poly(A) polymerase 
and other multisubunit complexes. Contributes to 
recognition of polyadenylation signal and may 
contribute to the differential recognition of various 
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RNAs. It also interacts with poly(A)polymerase 
(PAP) and CPSF160 forming a ternary complex in 
vitro, suggesting that they may act together in 
poly(A) site recognition and in recruitment of PAP 
to the RNA, thereby stimulating the otherwise 
weakly active and nonspecific polymerase (Preker et 
al., 1995). Stimulates poly(A) addition by binding to 
U-rich elements via arginine-rich RNA binding 
motif that lies within the C-terminus of the protein, 
thus significantly contributes to CPSF-mediated 
stimulation of PAP activity (Kaufmann et al., 2004). 
FIP1L1 also may act to tether poly(A) polymerase to 
the CPSF complex and may stabilize the association 
of PAP with the polyadenylation apparatus. 
Presumably act as a RNA modulator and active 
player in transformation from DNA to  
protein (Preker et al., 1995; Helmling et al., 2001; 
Kaufmann et al., 2004). Many unknown roles as the 
exact function of FIP1L1 is unknown. 
Implicated in 
Various cancers 
Diseases associated with FIP1L1 include 
eosinophilia-associated hematological malignancies, 
juvenile myelomonocytic leukemia (JMML) and 
acute promyelocytic leukemia (APL). FIP1L1 
rearrangements are associated with two distinct 
leukemogenic fusion genes: FIP1L1-PDGFRA 
(platelet-derived growth factor receptor alpha) and 
FIP1L1-RARA (retinoic acid receptor alpha) (Figure 
1). Genomic breakpoints in these rearrangements are 
variable, but FIP1L1 usually breaks within various 
introns (Vandenberghe et al., 2004; Iwasaki et al., 
2014). 
 
 
Figure 1. Mechanisms of FIP1L1 activation in hematologic malignancies. All known chimeric FIP1L1fusion proteins consists 
of the amino-terminal amino acids of FIP1L that includes the conserved FIP1 homology domain (40 amino acid Fip1 motif) and 
the carboxy-terminal part of the partner gene, thus the nuclear localization signal of FIP1L1 is absent in the fusion protein. To 
date, 2 fusions proteins of FIP1L1 are known: FIP1L1-PDGFRA and FIP1L1-RARA. While FIP1L1-PDGFRA is associated with 
hematologic disorders with primary eosinophilia, the FIP1L1-RARA fusion was identified in patients with JMML and APL, 
indicating that FIP1L1 may differentially contribute to the pathogenesis of distinct types of leukemia. In the FIP1L1-PDGFRa 
fusion protein, the C-terminal PDGFRA portion includes the entire kinase domain but only part of the autoinhibitory 
juxtamembrane region, making FIP1L1 dispensable for constitutive kinase activation that can be inhibited by administration of 
tyrosine kinase therapy (imatinib). FIP1 motif in FIP1L1-RARA seems to play a pivotal role in its homodimerization and 
repression of the retinoic acid response that is required for development of APL (adopted and modified from Gotlib et al., 2004). 
Abbreviations: N, N-terminal site; C, C-terminal site; TM, transmembrane domain; JM, juxtamembrane domain kinase, kinase 
domain; DBD, DNA binding domain; LBD, ligand binding domain; JMML, juvenile myelomonocytic leukemia; APL, acute 
promyelocytic leukemia. 
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FIP1L1-PDGFRA fusion in 
eosinophilia-associated 
hematological malignancies 
Note 
FIP1L1- PDGFRA (platelet-derived growth factor 
receptor, alpha) fusion have been reported in various 
neoplasms such as chronic eosinophilic Fusions 
leukemia, chronic neutrophilic leukemia, systemic 
mast cell disease, acute myeloid leukemia (AML) 
and T-cell lymphoblastic lymphoma, - all with 
overproduction of eosinophils in the blood and bone 
marrow; may be found in sporadic cases of myeloid 
sarcoma (granulocytic sarcoma) accompanied by or 
following AML. (Gotlib et al., 2004; Metzgeroth et 
al., 2007; Schmitt-Graeff et al., 2014). 
Prognosis 
Excellent with the use of tyrosine kinase inhibitors 
(imatinib). 
Cytogenetics 
The FIP1L1-PDGFRA fusion gene is the 
consequence of a cytogenetically invisible 
interstitial chromosomal deletion of approximately 
800 kb on chromosome band 4q12. Occasionally, 
FIP1L1-PDGFRA fusions are caused by 
chromosomal translocations such as t(1;4)(q44;q12) 
and t(4;10)(q12;p11). In both cases, the interstitial 
deletion creates an in-frame fusion and as a 
consequence genes between FIP1L1 and PDGFRA 
are deleted. 
Hybrid/Mutated gene 
5'FIP1L1-3'PDGFRA. 
Abnormal protein 
The encoded FIP1L1-PDGFRA fusion protein 
consists of the first 233 amino acids of FIP1L1 
(including the Fip1 motif) and the C-terminal part of 
PDGFRA, encompassing the truncated JM region 
and the entire kinase domain. 
Oncogenesis 
The genomic breakpoints within FIP1L1 have been 
found to be variably distributed (introns 9-13), 
whereas all breakpoints in PDGFRA are exclusively 
found within exon 12, which encompasses the 
juxtamembrane (JM) domain that is notable for its 
autoinhibitory function (The interruption of the JM 
domain of PDGFRA is a consistent feature of 
FIP1L1-PDGFRA fusions further underlying its 
functional significance in kinase activation (Walz et 
al., 2009; Iwasaki et al., 2014)). Similar to the BCR-
ABL1 fusion protein in chronic myeloid leukemia, 
FIP1L1-PDGFRA is a constitutively activated 
tyrosine kinase that is causally implicated in disease 
pathogenesis with potential evolution from chronic 
phase disease to disease progression as well as 
sensitivity to treatments with tyrosine kinase 
inhibitors such as imatinib (Cools et al., 2003; Jain 
et al., 2013). 
t(4;17)(q12;q21)/ FIP1L1/RARA 
Disease 
Juvenile myelomonocytic leukemia and acute 
promyelocytic leukemia. 
Prognosis 
Unknown, as only sporadic cases have been 
described. Reported cases described similar ATRA 
response of FIP1L1-RARA to that of PML-RARA 
fusions. 
Cytogenetics 
t(4;17)(q12;q21). 
Hybrid/Mutated gene 
In-frame fusion of 5'FIP1L1-3'RARA and 5'RARA-
3'FIP1L1.  
In all patients the rearrangement fused the RARA 
exon 3 with exon 15 (Buijs et al., 2007; Kondo et al., 
2008) or exon 13 of the FIP1L1 gene (Menezes et 
al., 2011), in a manner identical to all known RARA 
associated APL fusions. 
Abnormal protein 
832 amino acids; in-frame fusion protein composed 
of 428 amino-terminal amino acids of FIP1L 
(including the FIP1 homology domain) and 403 
terminal carboxyl-amino acids of RARA, including 
the DNA and ligand binding domains (Kondo et al., 
2008). Alternative splicing of the FIP1L1 portion 
results in multiple transcript variants similar to 
FIP1L1-PDGFRA distinct isoforms. 
Oncogenesis 
FIP1L1 is a subunit of the cleavage and 
polyadenylation specific factor (CPSF) complex that 
is involved in 3'-end mRNA processing, therefore it 
is possible that FIP1L1/RARA may interfere with 
FIP1L1 function (Kaufmann et al., 2004). On the 
other hand, retinoic acid receptor alpha (RARA), 
also known as NR1B1 (nuclear receptor subfamily 1, 
group B, member 1) is a nuclear receptor that is 
preferentially expressed in myeloid cells. 
Translocations that involve the RARA gene are 
characteristic findings in acute promyelocytic 
leukemia and several RARA partner genes have 
been identified resulting in various fusion gene 
products. In all known chimeric RARA fusions the 
homodimerization ability of fusion proteins appears 
to be critical for leukemic transformation as well as 
for repression of retinoic acid-responsive 
transcriptional activity. While FIP1L1 don't have the 
known protein-protein interaction domain, 
experimental studies with deletion mutants revealed 
that the FIP1 motif in FIP1L1-RARA plays a role in 
homodimer formation and transcriptional repressor 
activity. In fact, homodimer formation was 
demonstrated in all  
three identified isoforms of FIP1L1-RARA, as well 
as RARA-FIP1L1. In addition, FIP1L1-RARA 
associated with either FIP1L1-RARA or FIP1L1, but 
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not with RARA, further supporting the role of the 
FIP1L1 portion in homodimerization (Buijs et al., 
2007; Kondo et al., 2008; Iwasaki et al., 2014). The 
FIP1L1 promoter regulated expression may underlie 
these processes and may influence FIP1L1-RARA-
mediated leukemogenesis by differential gene 
expression of numerous potential target genes and 
activation of multiple signaling pathways. However, 
the molecular basis for FIP1L1-RARA- mediated 
leukemogenesis is most likely complex and still 
remains to be clarified. 
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